0669 The Role Of Hypersomnolence In Depression: Results From A Longitudinal Study Of The American General Population. (25th May 2022)

• Record Type: Journal Article
• Authors: Ohayon, Maurice; Pakpour, Amir; Cote, Marie Lise
• Is Part Of: Sleep. Volume 45(2022)Supplement 1
• Page Start: A293
• Page End: A294
• Publication Date: 2022-05-25
• Subjects: Sleep -- Physiological aspects -- Periodicals; Sleep disorders -- Periodicals; Sommeil -- Aspect physiologique -- Périodiques; Sommeil, Troubles du -- Périodiques; Sleep disorders; Sleep -- Physiological aspects; Sleep -- physiological aspects; Sleep Wake Disorders; Psychophysiology; Electronic journals; Periodicals; 616.8498
• DOI: 10.1093/sleep/zsac079.665
• Languages: English
• ISSNs: 0161-8105

Abstract

Abstract: Introduction: Insomnia symptoms have often been pointed out as an important factor for the relapse and/or the maintenance of depression. However, the contribution of hypersomnolence in depression is less studied and the conclusions are unclear. Our aim is to examine the association between hypersomnolence and depression in the US general population. Methods: This longitudinal study was carried out in eight states in the U.S. A total of 12, 218 subjects were interviewed by phone during the first wave (W1) and 10, 931 at the second wave (W2) three years apart. The analyses included only the subjects who participated in the 2 waves (N=10, 931). Hypersomnolence symptoms and Major Depressive Disorder (MDD) were assessed according to DSM-5 criteria. Results: At W1, 27.2% (95% CI 26.4%-28.0%) of the sample had at least one hypersomnolence symptoms listed in the DSM5 occurring at least 3 days per week. This prevalence at W2 was 26.4% (95% CI 25.6%-27.2%). The incidence of DSM5 hypersomnolence symptoms was 20.5% which represents a yearly incidence of 5.8%. For MDD, the prevalence was 5.1% (95% CI 4.7%-5.5%) and 4.2% (95% CI 3.8%-4.6%) in W1 and W2, respectively. At W1, 54.2% of participants with a MDD also had hypersomnolence. At W2, 50.7% of MDD subjects also reported hypersomnolence. After adjusting for age, gender and medical conditions, persistent hypersomnolence (i.e., reported at both interviews) predicted incident MDD (i.e., absent at the first interview but present at the follow-up) with a relative risk of 2.0 (95% CI 1.5-2.8). Similarly, persistent hypersomnolence predicted persistent MDD with a relative risk of 3.8 (95% CI 2.5-5.8). After adjusting for the presence of insomnia, persistent hypersomnolence remained a strong predictor for persistent MDD (RR: 2.4) but not for incident MDD. Conclusion: Hypersomnolence, especially when it is persistent, is an important contributing factor for persistent MDD. While the presence of insomnia mitigates the predictive value of hypersomnolence in incident MDD, it had little effect on the association between persistent hypersomnolence and persistent MDD. Support (If Any):